Is 25I-NBOMe legal in Trinidad and Tobago?

Legal status

25I-NBOMe is placed under the Dangerous Drugs Act, Chapter 11:25, on the reading recorded for Trinidad and Tobago, which was taken across the First and Second Schedules together with Legal Notice No. 345 of 2019. The dossier records «25i-nbome» against this row, and that is the term the Act was searched under rather than an entry the Act prints; it is reproduced character for character as the dossier holds it. That string is an alphanumeric code rather than a word in any language, so it reads identically in the dossier's record and in an English schedule, which is the one case where the recorded form and the printed form cannot diverge. The row reached that placement by the named schedule route, on a reading dated 20 September 2026. The boundary it had to settle before the entry could be assigned is that it checks the iodinated NBOMe name and does not substitute a generic phenethylamine category. Placement fixes what the material is for the Act and nothing beyond that: authorisation, purpose, any preparation exception and the conduct actually charged are separate questions, and sections 3 and 5 treat them separately.

Consequences if caught

Capital exposure: none. No limb of the Dangerous Drugs Act, Chapter 11:25, carries a capital penalty, so this row's placement does not move that answer in either direction, and the ceiling the Act reaches on a settled entry is life imprisonment rather than death. Trinidad and Tobago does retain capital punishment for murder, which is a different statute and a different offence, so a flat claim that the country has no death penalty would be wrong even where it is right about this Act. No per-substance amount is printed for this row at all. Section 5 of Chapter 11:25, as amended by Act No. 24 of 2019, supplies the trafficking ceiling and section 3 carries the possession offence, so the section charged rather than a printed weight is what sets the exposure. Nothing attaches to a street name. The exposure follows the identification, and what has to be identified here is an N-benzylmethoxy derivative built on a ring iodinated phenethylamine. The conduct charged does the rest of the work. Possession, possession for the purpose of trafficking and trafficking are different sections carrying different ceilings, and the same material will support any of them depending on what else is proved.

If prescribed or medical

The dossier records no traveller import scheme, no permit route and no prescription rule for Trinidad and Tobago, so this row defers on that branch rather than inventing one. The country level position that can honestly be stated is the general one: a foreign prescription is evidence about a patient, it is not a Trinidad and Tobago authorisation, and it does not become one at the border. Attached to this row, the placement is settled, which means that any lawful carry would have to rest on an authorisation and never on the amount. It has no therapeutic use and no dispensed form, so the prescription branch does not exist on this row at all.

Documentation

Nothing documents it. It is commonly sold on blotter at microgram doses, so a single small paper carrier can hold a substantial quantity, and the size of the carrier is not the measure. The entry recorded for this row, «25i-nbome», was read on 20 September 2026 across the First and Second Schedules of Chapter 11:25 and Legal Notice No. 345 of 2019. Whatever is carried, carry it in the container it was issued in, with the paper that names the patient, the substance, the dose and the period. A container separated from its label is the commonest way a lawful supply stops looking like one.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with Trinidad and Tobago’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.